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The emergence of resistance against current antibiotics calls for the development of new compounds to treat infectious diseases.
Synthetic pantothenamides are pantothenate analogs that possess broad-spectrum antibacterial activity in vitro in minimal me-
dia. Pantothenamides were shown to be substrates of the bacterial coenzyme A (CoA) biosynthetic pathway, causing cellular
CoA depletion and interference with fatty acid synthesis. In spite of their potential use and selectivity for bacterial metabolic
routes, these compounds have never made it to the clinic. In the present study, we show that pantothenamides are not active as
antibiotics in the presence of serum, and we found that they were hydrolyzed by ubiquitous pantetheinases of the vanin family.
To address this further, we synthesized a series of pantetheinase inhibitors based on a pantothenate scaffold that inhibited se-
rum pantetheinase activity in the nanomolar range. Mass spectrometric analysis showed that addition of these pantetheinase
inhibitors prevented hydrolysis of pantothenamides by serum.We found that combinations of these novel pantetheinase inhibi-
tors and prototypic pantothenamides like N5-Pan and N7-Pan exerted antimicrobial activity in vitro, particularly against Gram-
positive bacteria (Staphylococcus aureus, Staphylococcus epidermidis, Streptococcus pneumoniae, and Streptococcus pyogenes)
even in the presence of serum. These results indicate that pantothenamides, when protected against degradation by host
pantetheinases, are potentially useful antimicrobial agents.
There is a continuous battle between humans and microorgan-isms, and the development of resistance against current anti-
biotics creates a need to develop new drug scaffolds and targets
(1). There are several classes of antibiotic-resistant pathogens that
are emerging as major threats. Methicillin-resistant and vancomy-
cin-resistant Staphylococcus aureus strains (MRSA and VRSA) and
multidrug-resistant Streptococcus pneumoniae are serious health
problems in both hospital settings and the community. Multi-
drug-resistant Gram-negative bacteria (e.g., Escherichia coli, Kleb-
siella pneumoniae, and Pseudomonas aeruginosa) are a second
group of organisms that pose a threat of untreatable infections.
Finally, poverty-related conditions such as tuberculosis and para-
sitic diseases, which are particularly important in developing
countries, are a cause of great concern, as the already-limited
number of treatment modalities is decreasing because of resis-
tance. The development of new antibiotics has been slow, and
most compounds to date have been derived from a limited num-
ber of molecular scaffolds targeting a few microbial molecular
pathways. Discovery of new scaffolds and new targets should
clearly be a priority, although the commercial prospects of antibi-
otic development are unfavorable (1).
In 1970, amides derived from pantothenic acid (vitamin B5),
were reported to possess antibiotic activity in vitro (2). During the
last few decades, many of these pantothenamides have been syn-
thesized and the putative modes of action have been studied in
detail (3–10). Pantothenamides, of which N-pentylpantothena-
mide (N5-Pan) and N-heptylpantothenamide (N7-Pan) are the
prototypes, are active against Gram-negative (2) and Gram-posi-
tive (11) bacteria, but they have also been shown to possess activity
against fungi and malaria parasites (2, 8). Pantothenamides were
found to be substrates of the key rate-controlling enzyme panto-
thenate kinase (CoaA), and the rate of conversion of N5-Pan was
found to be more rapid than that of pantothenate itself. This led to
the conclusion that the mechanism of toxicity toward E. coli is due
to the formation of CoA analogs that lead to the transfer of an
inactive 4=-phosphopantothenamide moiety to acyl carrier pro-
tein (ACP), which is the first step in the bacterial type II route
(FASII) of fatty acid synthesis (10, 12). A recent study showed that
N5-Pan causes a 10-fold reduction of cellular CoA levels in E. coli
(7). The same study also showed that ethyldethia-ACP is readily
hydrolyzed by ACP-phosphodiesterase (AcpH). Neither overex-
pression of CoA biosynthetic enzymes nor pantothenate supple-
mentation could relieve growth inhibition by N5-Pan. These find-
ings indicate that the mechanisms by which pantothenamides
inhibit bacterial viability are not yet completely resolved.
Mammalian pantetheinases have only recently been discov-
ered. The first vanin gene to be cloned was the mouse vanin-1
(Vnn1) gene, which encodes a GPI-anchored leukocyte cell sur-
face protein of unknown function (13). Analysis of human vanins
revealed three gene family members named VNN1, -2, and -3,
clustered on chromosome 6 (14). The encoded proteins were
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shown to possess pantetheinase activity by the hydrolysis of
pantetheine into pantothenic acid (vitamin B5) and the low-mo-
lecular-weight thiol cysteamine (15). We found vanin family
members to be broadly expressed in nearly all human tissues (16).
On the basis of sequence similarities, vanins were classified as
members of the biotinidase branch of the nitrilase superfamily
(17). The most obvious function of biotinidases and pantethe-
inases is that of amidases involved in vitamin recycling.
In the present paper, we address the possible application of
pantothenamides as antibiotics, considering the current knowl-
edge on human pantetheinases. Based on the fact that vanins are
active on the carbon-nitrogen bond of pantetheine, we hypothe-
sized that antibiotic pantothenamides could also be hydrolyzed by
pantetheinase activity, which was indeed found to be the case. We
further show that inhibition of pantetheinase activity by novel
chemotypes that we recently developed (18) protects pantothena-
mides against hydrolysis and preserves their antibiotic activity.
We hereby provide proof of concept that combination of pantethe-
inase inhibitors with pantothenamides might be a novel antimi-
crobial strategy.
MATERIALS AND METHODS
Bacterial growth assays. Strains of Escherichia coli, Staphylococcus aureus,
Staphylococcus epidermidis, Streptococcus agalactiae, Streptococcus pyo-
genes, Klebsiella pneumoniae and Pseudomonas aeruginosa were grown
overnight in 1% Bacto tryptone medium (BD, Sparks, MD). Cultures
were then diluted 1:1,000 in fresh assay medium supplemented with or
without 20% fetal bovine serum (FBS; HyClone, Celbio, Logan, UT) or
20% decomplemented human serum (Sanquin Blood Bank, The Nether-
lands) and added to 96-well sterile enzyme-linked immunosorbent assay
(ELISA) plates (100 l per well). Moraxella catarrhalis was grown on
blood agar plates, and colonies were swabbed into in 1% Bacto tryptone
medium and diluted to an optical density at 600 nm (OD600) of 0.10.
Subsequently, 100l was added to 96-well sterile ELISA plates. The com-
pounds to be tested were diluted in the medium without serum and added
to the bacteria (100 l per well). Plates were incubated at 37°C, and bac-
terial growth was monitored over time by reading the optical density at
490 nm using a microplate reader (model 450; Bio-Rad Laboratories Inc.,
Hercules, CA). Streptococcus pneumoniae strains were grown to mid-log
phase (OD620 0.3) and stored in 15% glycerol at80°C till further use.
Bacteria were diluted 10-fold in Mueller-Hinton medium (BD, Sparks,
MD) and added to 96-well sterile ELISA plates (150 l per well). The
compounds to be tested were diluted in the medium without serum and
added to the bacteria (150l per well). Plates were incubated overnight at
37°C in 5% CO2. The MIC was defined as the lowest concentration of
pantothenamide at which no growth was visible.
Synthesis of pantothenamides and pantetheinase inhibitors. All re-
actions were performed under an argon atmosphere, unless stated other-
wise. Solvents were distilled from appropriate drying agents prior to use.
Triethylamine was distilled and stored over KOH. Reactions were fol-
lowed, Rf values were obtained using thin-layer chromatography (TLC)
on silica gel-coated plates (Merck 60 F254) with the indicated eluent, and
compounds were detected with UV light and/or by charring at ca. 150°C
after dipping into a solution of potassium permanganate or ninhydrin.
Column or flash chromatography was carried out using Acros silica gel
(0.035 to 0.070 mm; pore diameter, ca. 6 mm). IR spectra were recorded
on an ATI Mattson Genesis series Fourier transform infrared (FTIR) spec-
trometer. High-resolution mass spectra were recorded on a JEOL
AccuTOF (electrospray ionization [ESI]) or a MAT900 (electric ioniza-
tion [EI], chemical ionization [CI], and ESI) spectrometer. Melting points
were analyzed with a Büchi B-545 melting point apparatus and are not
corrected. Nuclear magnetic resonance (NMR) spectra were recorded
at 298 K on a Bruker DMX 300 spectrometer (300 MHz) and a Varian
400 (400 MHz) spectrometer in the solvent indicated in front of the
NMR data. Chemical shifts are given in parts per million (ppm) with
respect to tetramethylsilane (0.00 ppm) or CHD2OD (3.31 ppm) as the
internal standard for 1H-NMR and CDCl3 (77.16 ppm) or CD3OD
(49.00 ppm) as the internal standard for 13C-NMR. Coupling con-
stants are reported as J values in hertz (Hz). See the supplemental
materials and methods for details on the synthesis of pantothena-
mides. Details on the synthesis of pantetheinase inhibitors were de-
scribed by Jansen et al. (18).
Pantheteinase activity. Pantetheinase activity was measured by the
amount of free 7-amino-4-methylcoumarin (AMC) released by the hy-
drolysis of the pantetheine analogue pantothenate AMC (19). Pantothe-
nate AMC (final concentration, 10 M) was incubated in phosphate buf-
fer (100 mM potassium phosphate buffer pH 8.0) in the presence of serum
(1%) as the pantetheinase source with or without a potential pantethei-
nase inhibitor. Over time, samples were taken, and the reaction was ter-
minated by addition of 180 l 100 mM CaCO3 (pH 10.5). Fluorescence
was measured using a luminescence spectrometer (LS55; excitation wave-
length, 350 2.5 nm; emission wavelength, 450 2.5 nm; PerkinElmer)
against samples without serum as negative controls.
For mass-spectrometric analysis, 64 g/ml N7-Pan was incubated for
24 h at room temperature with 1% fetal bovine serum diluted in phos-
phate buffer (500 M potassium phosphate buffer, pH 8.0) with and
without the addition of 256 g/ml RR6.
Mass spectrometry analysis. Mass spectrometry was performed on a
JEOL JMS-T100CS spectrometer (AccuTOF CS) connected to a Agilent
1100 series high-performance liquid chromatography (HPLC) system.
Analysis was performed in infusion mode; 3 l of sample (1% sample in
methanol; HPLC grade; Fisher Scientific) was injected into a stream of
methanol (HPLC grade; Fisher Scientific) containing 0.1% formic acid
(puriss. p.a. for mass spectrometry; Fluka) and 50 nM PPG425 (polypro-
pylene glycol; average molecular weight, 425; Sigma-Aldrich Chemie
GmbH) for use as an internal mass drift compensator. Total analysis time
with a flow rate of 100 l/min was 2.5 min per sample. Sample informa-
tion elutes between 0.3 and 1.0 min. Data between 0 and 0.3 min were used
to mass drift compensate the calibration against PPG425 peaks, resulting
in a mass precision better than 2 ppm.
In vitro toxicity. Human embryonic kidney 293T cells were grown in
Dulbecco’s modified Eagle medium (DMEM-Glutamax; Gibco Invitro-
gen) containing 10% FBS (HyClone, Celbio, Logan, UT), 100g/ml pen-
icillin-streptomycin, and 1% pyruvate (Gibco Invitrogen) at 37°C and 5%
CO2. Pantothenamide or pantetheinase inhibitors were added to these
cultures for 48 h, and the effects on growth and toxicity were determined
microscopically. Cytotoxicity was detected using the LDH cytotoxicity
detection kit according to the manufacturer’s protocol (Roche Applied
Science, Indianapolis, IN). A rate of cell death of 100% was determined
after addition of 1% Triton X-100 to the cells.
Statistics. Data were analyzed using GraphPad Prism version 5. Data
are expressed as means standard deviations.
FIG 1 Effect of serum on pantothenamides. The growth-inhibiting effect of
N5-Pan on E. coli in media containing increasing amounts of serum was as-
sessed. In serum-free medium, a low concentration of N5-Pan is sufficient to
inhibit bacterial growth, while in a 1% serum medium, a high concentration
N5-Pan is needed for bacterial growth inhibition. In 10% serum, a high con-
centration of N5-Pan is insufficient to act as an antibiotic.n 4 for all samples.
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RESULTS
Pantothenamides are inactive as antibiotics in serum-contain-
ing medium. To test whether pantothenamides have antibiotic
activity under physiological conditions, E. coli was cultured in
minimal medium in the presence of complement-inactivated se-
rum (in this case, fetal bovine serum, but human serum gives
similar results). Addition of the prototypic pantothenamide N5-
Pan to log-phase cultures of E. coli in the absence of serum shows
the expected growth-inhibiting properties as described before (2)
(Fig. 1). Addition of 1% and 10% serum dose-dependently abol-
ishes the inhibitory effect of N5-Pan.
We next investigated if the effect of serum on pantothenamides
was due to a heat-labile factor. Figure 2A shows that heat-inacti-
vated serum (5 min at 100°C) is unable to interfere with N5-Pan-
mediated growth inhibition of E. coli. This made it very likely that
the effect was due to one or more proteins present in serum.
Pantothenamides are hydrolyzed in serum. Based on struc-
tural homology of pantothenamides with pantetheine and the
knowledge that pantetheine is hydrolyzed by pantetheinases of
the vanin family into pantothenic acid and cysteamine, we hy-
pothesized that this class of enzymes could also hydrolyze pan-
tothenamides. In a previous study, we showed that vanins are
ubiquitously expressed (16). Using an aminomethylcoumarine
derivative of pantothenic acid, which is a pantothenamide with
a fluorescent leaving group as a substrate (19), pantetheinase
activity in serum is readily detected. We found that this hydro-
lytic activity was completely abolished by heat inactivation of
the serum (Fig. 2B).
Subsequently, we investigated whether known antibiotic pan-
tothenamides are also hydrolyzed in the presence of serum. Mass-
spectrometric analysis of N7-Pan incubated in 1% serum for 24 h
revealed a complete disappearance of the N7-Pan peak, whereas a
clear peak of heptylamide, the expected hydrolysis product, ap-
pears (Fig. 3A). This indicates that pantothenamides are indeed
hydrolyzed in the presence of serum.
Pantetheinase inhibitors prevent degradation of antibiotic
pantothenamides in serum. We reasoned that inhibitors of se-
rum pantetheinases could prevent degradation of pantothena-
mides in biological fluids, thereby preserving their antibiotic ac-
tivity. As there were no selective high-affinity (subnanomolar)
pantetheinase inhibitors available, we designed and synthesized a
number of new inhibitors starting from pantetheine, the natural
substrate of pantetheinases, as a scaffold. A description of the syn-
thesis and characterization of these new chemotypes, pantetheine
analogs lacking the hydrolysable amide bond, has recently been
published (18). The most potent and selective inhibitor (RR6)
showed a 50% inhibitory concentration (IC50) of 40 nM against
pantetheinase activity present in human or bovine serum. See Ta-
ble S1 in the supplemental material for the structures and IC50s of
all compounds used here.
We next investigated if these pantetheinase inhibitors could
protect pantothenamide antibiotics from hydrolysis by serum
pantetheinase activity. Figure 3B shows the results of mass spec-
trometric analysis of N7-Pan incubated in 1% serum for 24 h in
the presence of 256 g/ml RR6. Whereas in Fig. 3A, a complete
disappearance of the N7-Pan peaks is observed and only the hy-
drolysis product heptylamine can be identified, Fig. 3B shows that
in the presence of RR6, the N7-Pan peaks are still present. Al-
though we found a minor peak corresponding to heptylamide, we
conclude that N7-Pan is clearly protected against hydrolysis by the
addition of a pantetheinase inhibitor.
In vitro antibiotic effects of combinations of pantothena-
mides and pantetheinase inhibitors. We next examined if inhi-
bition of serum pantetheinase could preserve the antibiotic effect
FIG 2 Inactivation of N5-Pan by serum is due to a heat-labile factor. (A)
N5-Pan (64 g/ml) (filled bars) does not inhibit growth of E. coli in the pres-
ence of FBS. Upon heat inactivation of serum (5 min at 100°C), N5-Pan effec-
tively inhibits bacterial growth. Open bars, bacterial growth without N5-Pan.
n 4 for all samples. (B) A pantetheinase activity assay showed pantetheinase
activity in serum () but none in inactivated serum (), confirming that
pantetheinases might be involved in pantothenamide inactivation.
FIG 3 Hydrolysis of N7-Pan is inhibited RR6. (A) Mass spectrometric analysis of a sample containing 1% serum and N7-Pan after 24 h incubation showed a
heptylamine peak but no N7-Pan-peak. Note that the produced pantothenic acid is only partially visualized with the settings used. (B) Pantetheinase inhibitor
RR6 is able to protect N7-Pan against hydrolysis, as clear peaks corresponding to the N7-Pan adducts are shown on the mass spectrum. Also, the RR6 adducts and
a very small peak corresponding to heptylamine were detected. The reaction was performed as described for panel A.
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of the pantothenamides N5-Pan and N7-Pan, which were previ-
ously reported to be active against strains of E. coli and S. aureus,
respectively. Figure 4 shows the effects of pantothenamides or a
pantetheinase inhibitor (RR6) alone and combinations of these.
The addition of pantothenamides had no antibacterial effect in
medium with 10% FBS, as shown before for N5-Pan (Fig. 1).
Similarly, the pantetheinase inhibitor RR6 on its own did not af-
fect growth of E. coli or S. aureus. Combination of RR6 with pan-
FIG4 Pantetheinase inhibition preserves the antibiotic effect of pantothenamides. (A) Growth curves ofE. coli andS. aureus, respectively, in 1% tryptone with 10% FBS
alone () or supplemented with 64 g/ml N5-Pan (), 256 g/ml RR6 (Œ), or a combination of N5-Pan and RR6 (). Only the combination of RR6 and N5-Pan
showed long-term growth inhibition ofE. coli.n 3 for all samples. (B) The conditions described for panel A were used, but N7-Pan instead of N5-Pan was added. Only
the combination of RR6 and N7-Pan resulted in S. aureus growth inhibition. n  3 for all samples. (C) Growth of E. coli and S. aureus in 1% tryptone with 10%
decomplemented human serum in the presence of different concentrations of RR6 and N5-Pan (E. coli) and N7-Pan (S. aureus). The checkerboard titration shows that
addition of RR6 increased the potency of pantothenamides in serum-containing media to concentrations comparable to cultures without serum, as shown in panel D.
n 2. (D) Growth of E. coli and S. aureus in 1% tryptone without serum in the presence of different concentrations of N5-Pan and N7-Pan, respectively. n 2.
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tothenamides, however, showed a clear antimicrobial effect for
N5-Pan on E. coli (Fig. 4A) and for N7-Pan on S. aureus (Fig. 4B).
We performed checkerboard titration of pantothenamides and
the pantetheinase inhibitor RR6 to obtain a range of MICs for the
combined compounds, as shown in Fig. 4C. The protective effect
of RR6 toward pantothenamides is clearly visible for both E. coli
and S. aureus. The amount of pantothenamides decreased to MIC
values in cultures without serum and RR6 (Fig. 4D).
Specificity and toxicity of pantothenamide antibiotics and
vanin inhibitors. The efficacy of pantothenamides has so far been
studied only in vitro on a limited number of bacterial species (2,
11). To delineate the taxa that are potential targets for antibiotic
therapy, we determined the MIC values for a number of clinically
relevant species. Table 1 shows that only Gram-positive bacteria
are sensitive to pantothenamides at pharmaceutically realistic
concentrations (8 g/ml). Sensitive species include S. aureus, S.
pneumoniae, S. pyogenes, and S. epidermidis. Within one genus
(Streptococcus), there is differential sensitivity, as S. agalactiae is
resistant, in contrast to S. pyogenes and S. pneumoniae. We tested
several strains of selected species for confirmation (see Table S2 in
the supplemental material).
As the putative mode of action of pantothenamides is at the
level of CoA-dependent biochemical pathways, this raised the
question of selectivity for microbial versus host targets. We there-
fore investigated if pantothenamides and pantetheinase inhibitors
were tolerated by mammalian cells. Using concentrations of N5-
Pan, N7-Pan, and RR6 up to 2,000 M, no effects on cell growth
or viability were observed in a human cell line (293T kidney cells)
(Fig. 5). Similar results were found on primary human keratino-
cytes (data not shown).
DISCUSSION
Here we provide detailed experimental evidence for the concept
that pantetheinase inhibitors can prevent the enzymatic degrada-
tion of pantothenamide antibiotics. Combination of a pantethe-
inase inhibitor with pantothenamides could be a successful strat-
egy to preserve the antibiotic properties of pantothenamides in the
presence of host pantetheinases. We propose that our data provide
proof of concept for a novel antibiotic strategy that could be used
against clinically relevant Gram-positive bacteria.
Since pantothenic acid was first described as a nutritional re-
quirement for most if not all organisms, its potential for antibiotic
drug design has been investigated. The different mechanisms by
which organisms were able to obtain pantothenic acid for CoA
biosynthesis and the relatively low homology between enzymes
involved in pantothenic acid processing opened the field to design
growth-inhibiting molecules specific for pathogens. Based on
pantothenic acid, different classes of molecules were described to
possess anti-bacterial, anti-fungal, and anti-parasitic activities in
vitro, including N-pantoyl-substituted amines, pantoylhydra-
zides, pantothenones, and pantothenamides (20). Most of these
analogues were expected to compete with endogenous panto-
thenic acid for the first enzyme of the CoA biosynthesis, CoaA. In
contrast, the working mechanism of pantothenamides is expected
to be different. Strauss and Begley (10) showed that N-pentylpan-
tothenamide is a substrate for CoA rather than an inhibitor. They
showed that the pantothenamide is completely processed to a CoA
analogue called ethyldethia-CoA and that the conversion is over
10 times faster than pantothenic acid processing. Subsequently,
Zhang et al. showed that acyl carrier protein (ACP) is the cellular
target, which results in an inactive ACP analogue that lacks the
sulfhydryl group for the attachment of acyl chains for fatty acid
synthesis (3). Mercer et al. have shown that pantothenamide
azido-pantetheine could be processed to ACP via FAS type II in
bacteria, while it cannot be processed via FAS type I in the human
cell line SKBR3 (21). Apparently, CoA analogues are recognized
only by type II fatty acid synthase, which is found in most bacteria,
while a FAS type I system is present in mammals and fungi. Be-
cause the structural arrangements of fungal and mammalian syn-
thases differ, selective pantothenamides could theoretically also
target fungal FAS type I. Assuming that pantothenamides target
the bacterial FASII pathway, administration of exogenous fatty
acids could potentially overcome the antibiotic effects of panto-
thenamides. Work by Zhang et al. showed that this is not the case
for E. coli. The MIC for S. pneumoniae, however, was increased





S. aureus ATCC 6538 N7-Pan 0.5
S. pneumoniae R6 N5-Pan 0.25
S. epidermidis ATCC 12228 N7-Pan 1
S. agalactiae RIVM 861352 None 256
S. pyogenes SS91 N5-Pan 0.5
E. coli ATCC 25922 N5-Pan 64
K. pneumoniae ATCC 43816 N5-Pan 32
M. catarrhalis RH4 N7-Pan 128
P. aeruginosa Xen41 None 256
FIG 5 In vitro toxicity of compounds. Cytotoxicity was measured on human embryonic kidney 293T cells treated with or without N5-Pan, N7-Pan, or RR6.
None of the tested compounds or combination resulted in increased cell death up to 2,000 M. Triton X-100 (1%) was added to cells to achieve 100%
cytotoxicity.
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4-fold, suggesting that pantothenamides target FASII but may also
have other effects (3). A recent paper by Parsons and Rock eluci-
dated the basis of differential susceptibility of Gram-positive bac-
teria to fatty acid synthesis inhibitors like cerulinin and platensi-
mycin (22). From this work it was concluded that fatty acids
cannot overcome FASII inhibition in S. aureus, in contrast to S.
pneumoniae. Whether this also holds for pantothenamides re-
mains to be investigated, as they are likely to inhibit other path-
ways in addition to FASII. This is supported by recent findings
indicating that, at least in E. coli, both holo-ACP and ethyldethia-
ACP can be hydrolyzed to Apo-ACP by ACP phosphodiesterase
(AcpH) (7). Those data suggest that the antibacterial effect of
N5-Pan is due to cellular depletion of CoA (7).
The first step in CoA biosynthesis is the phosphorylation of
pantothenic acid by pantothenate kinase (PanK), the key regula-
tory enzyme that is subject to self-regulation through feedback
inhibition by CoA. Structures of PanK enzymes among different
species have been investigated and showed differences in binding
capacity for pantothenic acid (23, 24). This might explain why
N5-Pan is more active againstE. coli and N7-Pan has specificity for
S. aureus. Binding features of human PanK family members with
pantothenic acid have not been investigated. Although structures
of human PanK1 and PanK3 in complex with acetyl-CoA have
been analyzed, the structure of human PanK isoforms in complex
with pantothenic acid would further facilitate the knowledge of
binding properties of PanK and thus would provide more insight
into possible modifications of pantothenic acid to aid medicinal
chemistry efforts.
We have no data on whether our pantetheinase inhibitors are
PanK substrates. We have shown that pantetheinase inhibitors by
themselves are not antibiotic, which suggests that they are not a
substrate for the CoA biosynthetic machinery. This may be caused
by the loss of the amide bond, which is likely to be a structural
requirement for entering the first step of CoA synthesis leading to
CoA antimetabolites, as recently suggested in a study by Mercer et
al. (5).
A recent publication identified pantetheinase inhibitors de-
rived from various chemical scaffolds in the LOPAC library, via a
high-throughput approach (19). These compounds are all nonse-
lective and have modest potency. As they are known to target
various mammalian cellular pathways at concentrations that are
lower than required for vanin inhibition, it is unlikely that these
compounds are useful in pharmacology or biological chemistry
approaches (25, 26).
The antibiotic strategy described here includes a combination
of an enzyme inhibitor and a molecule that interferes with bacte-
rial growth. Although a dual-compound formulation is not a pre-
ferred pharmaceutical approach, it is not unprecedented, as wit-
nessed by the use of beta-lactamase inhibitors (combined with
penicillin) and a dehydropeptidase inhibitor (combined with imi-
penem) (27). Here, we provide detailed experimental data for a
concept that we previously put forward (28, 29). Recently, indirect
evidence supporting this concept was found in the case of Plasmo-
dium falciparum growth inhibition by pantothenamides (30).
Obviously, a number of steps need to be taken before combi-
nation therapy of pantothenamide antibiotics and vanin inhibi-
tors can enter drug development. As witnessed by Fig. 4C, the
potency of our current vanin inhibitors needs to be improved to
achieve complete protection of pantothenamides in serum and to
maintain the required MIC values (31) (e.g., around 1g/ml for S.
aureus). We found a good bioavailability and pharmacodynamic
profile of the vanin inhibitor RR6 (18), which is encouraging for
further exploration of this possibility. Clearly, an increase of the
potency of current pantothenamides (N5-Pan and N7-Pan) is re-
quired. If this can be achieved, their application and sensitivity
may even extend beyond the Gram-positive species that we have
identified here.
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